# BMT CTN #0603 Haplo with RIC Data Submission - Documentation for Outcomes Dataset

# Outcomes dataset has 81 variables\* for 50 patients on BMT protocol #0603 Haplo with RIC and each patient has one record. This is the most important dataset in this data submission.

Notes in the last column of below table are provided by BMT CTN DCC to facilitate better understanding of the submitted datasets:

- **CRF** indicates this variable is from EMMES Case Report Form, as reported by the transplant center. The name of the CRF is shown in the column for easy reference.
- **EMMES** indicates this variable is from EMMES Enrollment System, as study implemented per protocol.
- **RECODE** indicates this variable is from computation for analysis purpose based on other data source. Algorithm and computation method are provided for reference.
- ERC indicates this variable is from the BMT #0603 Endpoint Review Committee adjudication. ERC adjudicated the data in a blinded manner based on the site-reported data in CRFs as well as some clinical notes from the sites. ERC –adjudicated outcomes should supersede the site-reported data if there would be any discrepancy.
- **CIBMTR** indicates this variable is data retrieval from the CIBTMR data system. CIBMTR data were reviewed by the CIBMTR physicians prior to the data transfer to Emmes DCC.

\*Note: The OUTCOMES dataset for the primary publication set has 78 variables. This is because donor chimerism (Marrow, Blood, T-cell) at Day 365 were not included in the primary manuscript and only included for the final data lock, recall that the primary endpoint was 6-month overall survival.

				Va	ariables in Cre	eation Order	
#	Variable	Туре	Len	Format	Informat	Label	Data Source / Notes
1	site	Char	5	5.	5.	Site Code	EMMES – this is the site code of the transplant center
2	SITENAME	Char	200	200.	200.	center name	EMMES– this is the name of the transplant center where the recipient was enrolled from
3	PROT	Char	5	5.	5.	BMT CTN Protocol #	EMMES – this indicated BMT CTN Protocol #
4	PATID	Char	15	15.	15.	Patient ID	EMMES - this is the blinded identifier that should be used for any data merge between this dataset and other datasets. This is unique for each patient in BMT CTN.
5	PROJID	Char	5	5.	5.	Project ID	EMMES - this is the blinded identifier that should be used for any data merge between this dataset and other datasets. This is unique for each patient in BMT CTN.
6	DONRAGHP	Num	8	4.	4.	Donor's Age	CRF - ENRA

				Va	riables in Cro	eation Order	
#	Variable	Туре	Len	Format	Informat	Label	Data Source / Notes
7	PRIMDIHP	Char	2	\$DIS.	2.	Primary Disease at Baseline	CRF - ENRA
8	CHEMREHP	Char	1	\$PRGM.	1.	Prior Regimens of Chemotherapy	CRF - ENRA
9	PRFSCOHP	Char	10	\$PSA.	10.	Performance Status at Baseline	CRF - ENRA
10	PRIORHP	Char	1	\$YESNO.	1.	Prior Autologous Transplant	CRF - ENRA
11	DOB	Num	8	MMDDYY8.	8.	Date of Birth	CRF – DEM
12	dsstage	Char	50			Disease Stage at Baseline	RECODE - this is computed based on the collected disease stage reported on ENRA form
13	ENRLDATE	Num	8	MMDDYY8.	8.	Enrollment Date	EMMES - this is the start date of the patient on this study.
14	ETHNIC	Char	3	\$ETHNICF.	3.	Ethnicity	CRF - DEM
15	GENDER	Char	1	\$GENDERF.	1.	Gender	CRF - DEM
16	raceA	Char	1	\$RACEF.		Race	RECODE - this is based on race and secondary race reported on DEM form and combine into

	Variables in Creation Order											
#	Variable	Туре	Len	Format	Informat	Label	Data Source / Notes					
							several big race categories.					
17	TXDTTXP	Num	8	MMDDYY8.	8.	Transplant Date	CRF - TXP					
18	fudate	Num	8	MMDDYY8.		Last followup date	RECODE - this is based on the last follow- up date from all available data sources including CRF, CIBMTR long term data and ERC adjudication					
19	DTHDT	Num	8	MMDDYY8.	8.	Date of Death	RECODE - this is based on death date from all available data sources including CRF-DTH and CIBMTR long-time data					
20	PRPLDATE	Num	8	MMDDYY8.	8.	Date of Relapse	RECODE - this is based on disease progression/relapse date from all available data sources including CRF-PRP, CIBMTR long-term data and ERC adjudicated data					
21	cGVHDdate_f	Num	8	MMDDYY8.	8.	Date of Diagnosis of Chronic GVHD	ERC - this is based on CIBMTR long term follow-up data and ERC adjudication on date of cGVHD					

	Variables in Creation Order											
#	Variable	Туре	Len	Format	Informat	Label	Data Source / Notes					
22	toxmax	Num	8			Maximum CTCAE Toxicity grade	RECODE - this is the maximum grade of Grades 3-5 toxicity that patient experienced, computed based on CRF-T12 data. If null, it indicates that patient's maximum toxicity grade was 0-2.					
23	HLAGVH_r	Char	4	\$4.	\$4.	HLA Typing Match Score (GVH direction)	ERC - this is based on CRF- HT1, HT2 collected variables and adjudicated by ERC					
24	HLAHVG_r	Char	5	\$5.	\$5.	HLA Typing Match Score (HVG direction)	ERC - this is based on CRF- HT1, HT2 collected variables and adjudicated by ERC					
25	COD_f	Char	21	\$21.	\$21.	Primary Cause of Death	ERC - this is based on primary cause of death reported on CRF- DTH form and adjudicated by ERC					
26	primarygf	Char	12	\$12.	\$12.	Primary Graft Failure	ERC - this is based on donor cell engraftment and chimerism assay data on CRF-NHM form and adjudicated by ERC					
27	secondgf	Char	3	\$3.	\$3.	Second Graft Failure	ERC - this is based on variables					

				Va	riables in Cre	eation Order	
#	Variable	Туре	Len	Format	Informat	Label	Data Source / Notes
							reported on CRF-SGR form and adjudicated by ERC
28	ANCDT1	Num	8	MMDDYY8.	8.	Date of Neutrophil Recovery	CRF - NHM
29	maxgrade	Num	8			Maximum Grade of Acute GVHD	ERC – This is the ERC adjudicated maximum overall grade of acute GVHD. ERC adjudicated the maximum grade based on the weekly acute GVHD assessment and some clinical notes as needed.
30	maxdate	Num	8	MMDDYY8.		Date of Maximum Acute GVHD	ERC – This is the ERC adjudicated date of maximum acute GVHD. ERC adjudicated the maximum grade based on the weekly acute GVHD assessment and some clinical notes as needed.
31	PLT201DT	Num	8	MMDDYY8.	8.	Date of Platelet Recovery to 20K	CRF - NHM
32	PLT501DT	Num	8	MMDDYY8.	8.	Date of Platelet Recovery to 50K	CRF - NHM

	Variables in Creation Order											
#	Variable	Туре	Len	Format	Informat	Label	Data Source / Notes					
33	Donor_relation	Char	16	\$16.	\$16.	Donor Relationship	CIBMTR					
34	age	Num	8	4.1		Age of patient (yrs) at enrollment	RECODE - this is the computed age of years at enrollment based on DOB on CRF-DEM form					
35	marrowpct28	Num	8			Donor Chimerism in Marrow at Day28	RECODE - this is computed based on marrow samples from CRF-NHM form for Day 28. If chimerism assay was not performed on marrow samples, used blood sample instead					
36	bloodpct28	Num	8			Donor Chimerism in Blood at Day28	RECODE - this is computed based on blood samples from CRF-NHM form for Day 28					
37	tcellpct28	Num	8			Donor Chimerism in T-Cell at Day28	RECODE - this is computed based on T-cell samples from CRF-NHM form for Day 28					
38	marrowpct56	Num	8			Donor Chimerism in Marrow at Day56	RECODE - this is computed based on marrow samples from CRF-NHM form for Day 56. If chimerism assay was not performed on marrow samples,					

[	Variables in Creation Order											
#	Variable	Туре	Len	Format	Informat	Label	Data Source / Notes					
							used blood sample instead					
39	bloodpct56	Num	8			Donor Chimerism in Blood at Day56	RECODE - this is computed based on blood samples from CRF-NHM form for Day 56					
40	tcellpct56	Num	8			Donor Chimerism in T-Cell at Day56	RECODE - this is computed based on T-cell samples from CRF-NHM form for Day 56					
41	marrowpct180	Num	8			Donor Chimerism in Marrow at Day180	RECODE - this is computed based on marrow samples from CRF-NHM form for Day 180. If chimerism assay was not performed on marrow samples, used blood sample instead					
42	bloodpct180	Num	8			Donor Chimerism in Blood at Day180	RECODE - this is computed based on blood samples from CRF-NHM form for Day 180					
43	tcellpct180	Num	8			Donor Chimerism in T-Cell at Day180	RECODE - this is computed based on T-cell samples from CRF-NHM form for Day 180					
44	marrowpct365	Num	8			Donor Chimerism in Marrow	RECODE - this is computed					

[				Va	ariables in Cre	eation Order	
#	Variable	Туре	Len	Format	Informat	Label	Data Source / Notes
						at Day365	based on marrow samples from CRF-NHM form for Day 365. If chimerism assay was not performed on marrow samples, used blood sample instead
45	bloodpct365	Num	8			Donor Chimerism in Blood at Day365	RECODE - this is computed based on blood samples from CRF-NHM form for Day 365
46	tcellpct365	Num	8			Donor Chimerism in T-Cell at Day365	RECODE - this is computed based on T-cell samples from CRF-NHM form for Day 365
47	maxcgvhd_f	Char	9			Maximum Grade of Chronic GVHD	RECODE - this is based on CRF-CGV form, CIBMTR long term follow-up data and ERC adjudicated maximum cGVHD grade
48	ag24date	Num	8	MMDDYY8.		Date of Grades 2 to 4 Acute GVHD	RECODE - this is based on date of maximum aGVHD and maximum 2 to 4 aGVHD grades
49	ag34date	Num	8	MMDDYY8.		Date of Grades 3 to 4 Acute GVHD	RECODE - this is based on date of maximum aGVHD and

	Variables in Creation Order											
#	Variable	Туре	Len	Format	Informat	Label	Data Source / Notes					
							maximum 3 to 4 aGVHD grades					
50	ost_srvtm	Num	8			Overall Survival Post Transplant (days)	RECODE - this is the days from date of transplant to the death or last follow up, computed for overall survival					
51	ost_mon	Num	8			Overall Survival Post Transplant (months)	RECODE - this is the months from date of transplant to the death or last follow up, computed for overall survival					
52	ost_outcome	Char	9			Overall Survival Post Transplant Outcome	RECODE - this is the outcome for overall survival endpoint					
53	ost_srvcens	Num	8			Overall Survival Post Transplant Censor Indicator	RECODE - this is the censor indicator for overall survival					
54	dfs_srvtm	Num	8			Progression-Free Survival Post Transplant (days)	RECODE - this is the days from date of transplant to the death, relapse, or last follow up, computed for disease progression-free					
55	dfs_mon	Num	8			Progression-Free Survival Post Transplant (months)	RECODE - this is the months from date of transplant to the					

				١	/ariables in Cre	eation Order	
#	Variable	Туре	Len	Format	Informat	Label	Data Source / Notes
							death, relapse or last follow up, computed for disease progression-free
56	dfs_outcome	Char	9			Progression-Free Survival Post Transplant Outcome	RECODE - this is the outcome for disease progression-free endpoint
57	dfs_srvcens	Num	8			Progression-Free Survival Post Transplant Censor Indicator	RECODE - this is the censor indicator for disease progression-free
58	TRMday	Num	8			Treatment-related Mortality Post Transplant(days)	RECODE - this is the months from date of transplant to date of treatment-related mortality
59	TRMoutcome	Char	9			Treatment-related Mortality Post Transplant Outcome	RECODE - this is the outcome for treatment-related mortality endpoint
60	TRM_CI	Num	8			Treatment-related Mortality Post Transplant Indicator for Cumulative Incidence(event=1)	RECODE - this is the indicator for cumulative incidence of treatment-related mortality (0=End Study, 1=Death, 2=Relapse) Relapse is considered as a competing risk

				١	Variables in Cro	eation Order	
#	Variable	Туре	Len	Format	Informat	Label	Data Source / Notes
							in the cumulative incidence analysis for TRM.
61	relapseday	Num	8			Relapse Post Transplant(days)	RECODE - this is the days from transplant date to date of relapse (=PRPLDATE - TXDTTXP)
62	relapseoutcome	Char	9			Relapse Post Transplant Outcome	RECODE - this is the outcome for relapse post transplant
63	relapse_CI	Num	8			Relapse Post Transplant Indicator for Cumulative Incidence(event=1)	RECODE - this is the indicator for cumulative incidence of relapse (0=End Study, 1=Relapse, 2=Death) Death is considered a competing risk in the cumulative incidence analysis for relapse.
64	ancday	Num	8			Neutrophil Recovery Post Transplant(days)	RECODE, this is the days from date of transplant to date of neutrophil recovery (=ANCDT1 - TXDTTXP)
65	ancoutcome	Char	9			Neutrophil Recovery Post Transplant Outcome	RECODE - this is the outcome for neutrophil recovery endpoint

	Variables in Creation Order											
#	Variable	Туре	Len	Format	Informat	Label	Data Source / Notes					
66	anc_CI	Num	8			Neutrophil Recovery Post Transplant Indicator for Cumulative Incidence(event=1)	RECODE - this is the indicator for cumulative incidence of neutrophil recovery (0=End Study, 1=Engraft, 2=Death) Death is considered a competing risk in the cumulative incidence analysis for neutrophil recovery.					
67	plt20day	Num	8			Platelet Recovery to 20K Post Transplant(days)	RECODE, this is the days from date of transplant to date of platelet recovery to 20K ( <i>=plt201dt - TXDTTXP</i> ).					
68	plt20outcome	Char	9			Platelet Recovery to 20K Post Transplant Outcome	RECODE - this is the outcome of platelet recovery to 20K.					
69	plt20_Cl	Num	8			Platelet Recovery to 20K Post Transplant Indicator for Cumulative Incidence(event=1)	RECODE - this is the cumulative incidence indicator of platelet recovery to 20K (0=End Study, 1=Engraft, 2=Death). Death is considered as a competing risk.					
70	plt50day	Num	8			Platelet Recovery to 50K Post Transplant(days)	RECODE - this is days from date of transplant to date of platelet recovery to 50K ( <i>=plt501dt</i> - <i>TXDTTXP</i> ).					

	Variables in Creation Order						
#	Variable	Туре	Len	Format	Informat	Label	Data Source / Notes
71	plt50outcome	Char	9			Platelet Recovery to 50K Post Transplant Outcome	RECODE - this is the outcome of platelet recovery to 50K.
72	plt50_CI	Num	8			Platelet Recovery to 50K Post Transplant Indicator for Cumulative Incidence(event=1)	RECODE - this is the cumulative incidence indicator for platelet recovery to 50K (0=End Study, 1=Engraft, 2=Death). Death is considered as a competing risk.
73	cgvhdday	Num	8			Chronic GVHD Post Transplant(days)	RECODE - this is the days from date of transplant to date of maximum chronic GVHD (=DTDGNCGV -TXDTTXP).
74	cgvhdoutcome	Char	9			Chronic GVHD Post Transplant Outcome	RECODE - this is the outcome indicator for chronic GVHD Post Transplant endpoint.
75	cgvhd_CI	Num	8			Chronic GVHD Post Transplant Indicator for Cumulative Incidence(event=1)	RECODE - this is the cumulative incidence indicator for chronic GVHD post transplant endpoint. (0=End Study, 1=cGVHD, 2=Death) Death is considered a competing risk in the cumulative incidence analysis for chronic GVHD.

	Variables in Creation Order						
#	Variable	Туре	Len	Format	Informat	Label	Data Source / Notes
76	agvhd24day	Num	8			Grades 2-4 Acute GVHD Post Transplant(days)	RECODE - this is days from transplant to date of Grade 2-4 acute GVHD ( <i>=ag24date-</i> <i>TXDTTXP</i> ).
77	agvhd24outcome	Char	9			Grades 2-4 Acute GVHD Post Transplant Outcome	RECODE - this is the outcome of Grades 2-4 acute GVHD Post Transplant endpoint
78	aGVHD24_CI	Num	8			Grades 2-4 Acute GVHD Post Transplant Indicator for Cumulative Incidence(event=1)	RECODE - this is the cumulative incidence indicator for Grades 2- 4 acute GVHD post transplant endpoint. (0=End Study, 1=g24aGVHD, 2=Death) Death is considered a competing risk in the cumulative incidence analysis for acute GVHD.
79	agvhd34day	Num	8			Grades 3-4 Acute GVHD Post Transplant(days)	RECODE - this is days from date of transplant to date of Grade 3-4 acute GVHD ( <i>=ag34date-</i> <i>TXDTTXP</i> ).
80	agvhd34outcome	Char	9			Grades 3-4 Acute GVHD Post Transplant Outcome	RECODE - this is the outcome of Grades 3-4 acute GVHD Post Transplant endpoint

	Variables in Creation Order						
#	Variable	Туре	Len	Format	Informat	Label	Data Source / Notes
81	aGVHD34_CI	Num	8			Grades 3-4 Acute GVHD Post Transplant Indicator for Cumulative Incidence(event=1)	RECODE - this is the cumulative incidence indicator for Grades 3- 4 acute GVHD post transplant endpoint. (0=End Study, 1=g34aGVHD, 2=Death) Death is considered a competing risk in the cumulative incidence analysis for acute GVHD.

# Algorithm used for the Recode and ERC Adjudications

#### Algorithm for Acute GVHD Grade:

- The acute GVHD algorithm calculates the grade based on the organ (skin, GI and liver) stage and etiology/biopsy reported on the weekly GVHD form.
- If none of the etiologies for skin, upper GI, lower GI, or liver are reported as GVHD, then the overall grade is 0
- If multiple etiologies are specified for lower GI or liver, the organ system will be down-staged by 1.
- If an upper GI biopsy is negative, upper GI symptoms are down-staged.
- If GVHD is not listed as an etiology for upper GI then upper GI symptoms are down-staged.
- Each organ contributes to the overall grade; while to get an overall grade, it does not necessarily need all organ symptoms. Different organ/stage determine different grade. Details below:

Grad	e 0:	Grade III:		
	No skin rash and	Skin-No rash to Rash > 50% with		
	No protracted nausea and vomiting	Diarrhea > 1000 or severe abdominal pain or		
and		Bilirubin 3.1 - 15		
	No diarrhea or diarrhea < 500 and			

Bilirubin < 2.0	
Grade I:	Grade IV:
Skin rash 25-50% and	Skin-Generalized Erythroderma with Bullus
No diarrhea or diarrhea < 500 and	Formation and Desquamation or
Bilirubin < 2.0	Bilirubin > 15
Grade II:	
Skin rash >50% or	
Diarrhea >500 or	
Bilirubin 2.0 - 3.0 or	
Persistent nausea/vomiting	

## Algorithm for Chronic GVHD: Limited vs Extensive (Definition from CIBMTR forms)

- Limited localized skin involvement and/or hepatic dysfunction due to chronic GVHD
- Extensive one or more of the following:
  - 1. generalized skin involvement; or,
  - 2. liver histology showing chronic aggressive hepatitis, bridging necrosis or cirrhosis; or,
  - 3. involvement of eye: Schirmer's test with < 5 mm wetting; or
  - 4. involvement of minor salivary glands or oral mucosa demonstrated on labial biopsy; or
  - 5. involvement of any other target organ

### Note on the sample size:

There were fifty-five patients enrolled to BMT CTN 0603. The endpoint review committee adjudicated 50 of them to be eligible for the study. The OUTCOMES dataset only include data for the 50 patients.

Per protocol the study patients are followed for one year after transplantation. The median survival post-transplant for primary publication dataset is 356 days with range [103, 441]. After incorporating CIBMTR long-term follow-up data, the median survival in the final data lock set is1081 days with range [738, 1461].